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Summary 
Interactions mediated by TCRs expressed on different 
T cell subsets may play a role in immunoregulation. 
To investigate this idea, we studied the regulation of 
superantigen-induced TCR VJ~-restricted responses. 
We asked whether the in vivo regulation of CD4 ÷ Vp8 ÷ 
T cells following SEB injection is controlled by CD8 ÷ 
T ceils. We found that in mice deficient in CD8 ÷ T cells, 
the down-regulation of CD4 + Vp8 + T ceils below base- 
line is not observed. Moreover, following SEB admin- 
istration, CD8 ÷ T cells emerge that preferentially kill 
subpopulations of activated CD4 ÷ VI~8 + but not CD4 ÷ 
Vp8- T cells in vitro. This TCR Vp-specific cytotoxicity 
is dependent on 132-microglobulin and is inhibited by 
antisera specific for Qa-1 but not by antibody to MHC 
class la. These data suggest the idea that the specific- 
ity of immune regulation may involve CD8 ÷ T cell rec- 
ognition of TCR Vp determinants and Qa-1 molecules 
expressed on CD4 + T cells. 
Introduction 
The immune response is controlled in part by a complex 
interaction of T cells. Recently, superantigens have been 
used as a model to study these complex interactions both 
in vitro and in vivo, because they trigger immune responses 
by stimulating particular TCR V13 chains. The administra- 
tion of different superantigens to mice is followed by rapid 
changes in the populations of circulating T lymphocytes. 
For example, after intravenous injection of the superanti- 
gen staphylococcus enterotoxin B (SEB), there is an initial 
deletion (12-24 hr) followed by an expansion and a second 
phase of deletion (after day 4) of CD4 ÷ and CD8 + T cells 
that express T cell receptor (TCR) VI38 chains (Gonzalo 
et al., 1994; Kawabe and Ochi, 1991; Rellahan et al., 
1990). The increase in CD4 ÷ Vl~8 + and CD8 ÷ VI38 + T cells 
reaches a maximum on day 4 and by day 8 returns to 
background. However, the CD4 ÷ VI38 + but not the CD8 ÷ 
V~8 ÷ T cell population is further deleted, becomes reduced 
to about 30%-40% below baseline, and remains at this 
reduced level for at least 21 days. The mechanism of this 
delayed deletion of CD4 ÷ T cells following SEB administra- 
tion is unknown. Although it is known that triggering of 
the TCR alone by either superantigen or anti-TCR antibod- 
ies can induce apoptosis (Takahashi et al., 1989; Lenardo, 
1991; Boehme and Lenardo, 1993), other mechanisms 
requiring interactions with other immunoregulatory cells 
may also contribute to the deletion of CD4 ÷ T cells. The 
mechanism of CD4 ÷ T cell deletion in this context is of 
interest, because it might shed light on the mechanisms 
of T lymphocyte regulation in general. 
In this regard, we previously demonstrated that CD8 ÷ 
T cells mediate the resistance to murine experimental al- 
lergic encephalomyelitis (EAE), which is induced by the 
1-9Nac peptide of myelin basic protein (Jiang et al., 1992). 
We confirmed that mice that had recovered from an initial 
episode of EAE were resistant to a second challenge of 
antigen. However, animals depleted of CD8 ÷ T cells by 
anti-CD8 antibody in vivo were no longer resistant. A simi- 
lar protective role of CD8 ÷ cells was demonstrated by oth- 
ers studying the induction of EAE in CD8 gene knockout 
mice (Koh et al., 1992). Although the mechanism by which 
CD8 ÷ T cell depletion rendered the animals susceptible 
to disease following a second challenge of antigen was 
unclear, we considered the possibility that CD8 ÷ T cells 
functioned to down-regulate the CD4 ÷ myelin basic pro- 
tein-reactive ffector T cells that mediate EAE. 
To study more readily the role of CD8 ÷ T cells in regulat- 
ing CD4 ÷ T cells, we asked whether, in the current studies, 
the deletion of CD4 ÷ T cells expressing the VI38 TCR in 
SEB-treated animals involved CD8 ÷ T cells. We used two 
kinds of CD8 ÷ T cell-deficient animals to study the role 
of CD8 ÷ T cells in regulating CD4 ÷ T cells in vivo. First, 
in experiments analogous to those described in EAE, we 
investigated mice depleted of CD8 + T cells by injection of 
anti-CD8 antibody in vivo (Jiang et al., 1992). Second, we 
studied 132m -~- mice, which are known to be deficient in 
CD8 ÷ T cells (Zijlstra et al., 1990). In both systems, we 
provided evidence that CD8 ÷ T cells participated in SEB- 
induced deletion of CD4 ÷ VI38 ÷ T cells in vivo. In an attempt 
to understand the possible mechanisms involved in such 
T-T cell interactions, we established an in vitro cytolytic 
system, and asked whether CD8 ÷ T cells stimulated by 
SEB-activated autologous CD4 ÷ VI38 + T cells will specifi- 
cally kill CD4 ÷ T cell targets expressing Vl38 TCR. We 
demonstrated that CD8 ÷ T cells derived from SEB-primed 
mice could be restimulated in vitro and were cytotoxic to 
the specific CD4 ÷ T cell targets based on their TCR VI3 
expression. Fu rthermore, this autologous TC R VI3-specific 
cytolysis was 132m dependent. Quite surprisingly, this cyto- 
lytic interaction between CD8 ÷ effector cells and CD4 ÷ tar- 
gets was blocked by antisera to a MHC class Ib molecule, 
Qa-1, but not by antibody to classical MHC class la mole- 
cules. Thus, these data suggest that a subset of CD8 ÷ T 
cells can be induced by activated CD4 ÷ T cells to kill the 
inducer CD4 ÷ T cells, through the recognition of their TCR 
VI~ chains or the peptides derived from their TCR VI3 chains 
in Conjunction with Qa-1. We speculate that such a pro- 
cess may be involved in the regulation of other immune 
responses in vivo. 
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Figure 1. CD8 ÷ T Cell Depletion Protects CD4 + V1~8.1,2 +T Cells from 
SEB-Induced T Cell Death 
The experiments were done in BALB/c mice as described in Experi- 
mental Procedures. The group designations are the following: CD8+/ 
PBS, PBS-primed CD8 ÷ T cell nondepleted; CD8-/PBS, PBS-primed 
CD8 ÷ T cell depleted; CD8+/SEB, SEB-primed CD8 ÷ T cell nonde- 
pleted; CD8 /SEB, SEB-primed CD8 + T cell depleted. The value for 
day 1 is the average of >50 normal mice. For days 4, 7, 14, and 21, 
each point represents the average of the data of 12-18 mice from 
three separate xperiments. 
Results 
The In Vivo Delayed Deletion of CD4 + Vp8 + T Cells 
Following SEB Administration Is Markedly Reduced 
by In Vivo Treatment of Mice with Anti-CD8 Antibody 
Following treatment of animals with SEB, there is an initial 
rapid deletion of CD4 + T cells followed by an expansion 
of those T cells that express the characteristic VI3 segment 
reactive with SEB. Subsequently, there is a delayed dele- 
tion below background level of the T cells expressing the 
Vies reactive with SEB (Gonzalo et al., 1994; Kawabe and 
Ochi, 1991; Rellahan et al., 1990). To address whether 
CD8 ÷ T cells are involved in th is delayed TCR VI3-restricted 
deletion following SEB administration to mice, we com- 
pared the effect of SEB on CD4 ÷ VI38 + populations of T 
cells in normal mice and in mice depleted of CD8 ÷ cells 
by in vivo administration of anti-CD8 antibody. We injected 
50 p.g SEB intravenously into both untreated and CD8 ÷ T 
cell-depleted mice, and the portion of CD4 ÷ VI38.1,2 + T 
cells (which are specifically interactive with SEB) in periph- 
eral CD4 + T cells of those mice was determined. As shown 
by Figure 1A and Table 1, in SEB-primed CD8 ÷ mice, the 
number of CD4 ÷ VI38.1,2 + T cells increased until day 4 and 
then decreased, reaching a low point between day 7 and 
day 14, and remained low for at least another week. In 
the CD8 + T cell-depleted mice treated with SEB, the num- 
ber of CD4 ÷ VI38.1,2 ÷ T cells also increased after SEB 
injection, reached a peak on day 4, and then slowly re- 
turned to baseline levels by day 14. The decrease (25O/o - 
30%) below normal levels in the percentage of CD4 ÷ 
VI38.1,2 + T cells that is observed in normal mice treated 
with SEB was completely eliminated by the depletion of 
CD8 ÷ T cells. Both SEB-induced T cell death and the pro- 
tection due to CD8 ÷ T cell depletion were TCR VI3 specific, 
because there was no difference in the numbers of CD4 ÷ 
Vl~6 ÷ T cells between CD8 ÷ T cell-nondepleted and CD8 ÷ 
T cell-depleted SEB-primed mice (Figure 1B; Table 1). 
These data confirm that following SEB injection in normal 
mice, there is an initial proliferation of CD4 + VI38 T cells 
followed by a decrease in the number of CD4 ÷ Vl38 ÷ cells 
below baseline. Further, the data demonstrate that the 
decrease of CD4 ÷ VI38 ÷ T cells below baseline is CD8 ÷ T 
cell dependent, because this decrease is observed only 
in untreated mice containing CD8 + T cells, but not in CD8 ÷ 
T cell-depleted mice. 
The In Vivo Deletion of CD4 ÷ Vl~8 + T Cells Following 
SEB Administration Is Abrogated in p2m -/- Mice 
To verify further the importance of CD8 ÷ cells in the in vivo 
deletion below the baseline of CD4 ÷ Vl~8 + cells following 
SEB administration, we next studied J32m ~ mice known 
to lack mature CD8 ÷ T cells. The ~2m-/-mice used were 
derived from a C57BL (B6) x 129 cross and are H-2 b (Zijl- 
stra et al., 1989; Muller et al., 1992). We used both B6 and 
(B6 x 129)F2 mice as control animals. In two separate 
experiments, peripheral CD4 ÷ V~8.1,2 ÷ cells in SEB- 
primed l~2m -~- mice increased on day 4, returned to and 
remainedat normal level after day 7 (Table 2). In contrast, 
the CD4 ÷VI38.1,2 ÷ cells are reduced to greater than 30% of 
baseline in both SEB-primed control B6 and (B6 x 129)F2 
mice. It is curious that in these experiments, unlike our 
experience in BALB/c mice, there was no CD4 ÷ VI38 + T 
cell expansion observed by day 4 in both B6 and (B6 x 
129)F2 mice. It is possible that V138-specific CD8 ÷ T cells 
involved in the regulation of CD4 ÷ T cells arise earlier in 
these mice. 
The In Vitro Generation of CD8 ÷ Killer Cells Specific 
for CD4 ÷ Vp8 + Target Cells 
The requirement for CD8 ÷ T cells made it unlikely that the 
deletion of CD4 ÷ Vl38 ÷ T cells following SEB administration 
was only owing to an endogenous self-destruction pro- 
gram activated by SEB. Moreover, the specificity of the 
deletion raised the possibility that the initial SEB-induced 
CD4 ÷ VI38 ÷ T cells further stimulated a population of CD8 + 
T effector cells with anti-VI38 specificity (distinct from the 
CD8 + VI38 + T cells directly stimulated by SEB). We hypoth- 
esized that these CD8 ÷ T cells could then mediate the 
CD8 T Cells Recognizing Vl38 ÷ T Cells: Role of Qa-1 
187 
Table 1. Analysis of VI38.1,2 and VI~6 Expression on Peripheral T Cells in CD8+T CelI-Nondepleted and CD8 ÷ T Cell-Depleted 
BALB/c Mice a 
Percentage of Total 
CD4 ÷ T Cells CD8 ÷ T Cells 
Anti-CD8 Treatment Injection V138.1,2 VI36 VI38.1,2 VI36 
No PBS 18.7 _+ 0.84 11.4 -*- 0.20 25.5 ± 0.49 12.2 ± 1.4 
Yes PBS 19.1 ± 0.21 11.6 ± 0.32 - - 
No SEB . 13.0 --_ 2.40 12.7 ± 0.44 29.1 ± 4.8 11.6 + 3.0 
Yes SEB 18.0 ± 0.31 11.9 ± 0.90 - - 
a Experiments were done as in Figure 1. This table shows the data of expression of V1~8.1,2 and VI36 in CD8 + T cell-nondepleted and CD8 ÷ T 
cell-depleted mice 14 days after SEB injection. Each value represents data of 12-18 mice from three separate experiments. 
deletion of CD4 ÷ VI38 + T cells by a cytotoxic mechanism. 
To test this hypothesis in vitro, we first established a CD4 ÷ 
VI38 ÷ T cell line by stimulating purified CD4 + V[.~8 ÷ T cells 
with SEB. This line was then irradiated and used to induce 
CD8 ÷ VI38- T cell lines in vitro. Since the superantigen 
SEE does not react with T cells bearing VI38 TCR (Marrack 
and Kappler, 1990), we have used SEB and SEE to obtain 
CD4 + T cell lines bearing different TCR VI3 specificities, 
including the generation of VI~8 ÷ and VI38 cell lines. 
To address the function and specificity of these CD8 + 
T cell lines, we asked whether these cells could specifically 
kill the CD4 ÷ stimulating T cells that were used to induce 
them in the initial instance. In preliminary studies, we 
found that the CD8 ÷ T cells initially induced by CD4 ÷ VI58 ÷ 
cells could specifically kill CD4 ÷ VI.~8 ÷ targets to a greater 
extent than CD4 + V158 targets in a conventional ~lCr re- 
lease assay, but only after prolonged periods of incubation 
(>12 hr). However, incubation times greater than 12 hr 
were often associated with a high spontaneous release 
of ~1Cr from targets that significantly reduced the signal-to- 
noise level, increased the experimental variability, and 
made the interpretation of experiments difficult. During 
the course of these studies, we observed that the reduction 
(due to lysis) of CD4 ÷ VI38 ÷ T cells following coculture with 
effector CD8 ÷ T cells and CD4 ÷ VI38- T cells leads to a 
reduced ratio of CD4 ÷ VI38 + to CD4 ÷ VI38 that could be 
precisely enumerated by two-color FACS. This method 
of measuring specific cytotoxicity permitted analysis of 
cocultured effector and target cells for greater than 24 
hr. To demonstrate that the FACS cytolytic T lymphocyte 
(CTL) method gives quantitative results comparable to 
conventional 51Cr release assays, a murine alloantigen- 
specific CTL line of L3 cells (H-2 b) was tested simultane- 
ously for its specific CTL activity to the specific targets, 
P815 cells (H-2~), and nonspecific targets, EL4 cells (H-2b), 
in both FACS and 5~Cr release assays. Similar CTL activi- 
ties were obtained using both assays at effector:target 
ratio from 5 to 1.25 (Figure 2; Table 3). By FACS assay, the 
ratio of H-2 d÷ to H-2 ~ targets clearly decreased in cultures 
containing anti-H-2 ~ killers (Figure 2b) compared with cul- 
tures without effector cells (Figure 2a). 
Using the FACS CTL assay, we next tested the specific- 
ity of the CD8 ÷ VI58 cell lines. In particular, we asked 
whether the CD8 ÷ T cell line cells initially induced by CD4 ÷ 
VI38 ÷ cells specifically kill CD4 ÷ VI38 ÷ targets. The results, 
using four independent CD8 ÷ VI~8- T cell lines (CTL-1-4) 
cocultured for 24 hr with target populations containing var- 
ying numbers of CD4 ÷ Vl~8 + and CD4 ÷ VI38 T cells in five 
separate experiments, are shown in Table 4. The target 
cell populations were derived from cultures of CD4 ÷ cells 
triggered by varying ratios of the superantigens SEB to 
Table 2. Analysis of V1~8.1,2 TCR Expression on Peripheral 
CD4 ÷ T Cells in 132m-J- mice after SEB Stimulation ~
Experi- CD4 ÷ V!58+/Total CD4 ÷ 
ment (Percentage) Time (Days) 
num- Injec- 
ber Mice tions 4 7 14 21 60 120 
B6 PBS 18.6 18.8 18.6 18.5 - - 
B6 SEB 18.1 11.2 12.2 13.0 - - 
1~2m -~ PBS 18.5 18.6 18.6 18.5 - 19.1 
l~2m -I SEB 24.2 18.7 18.5 18.6 - 19.3 
(B6 x 129)F2 PBS 18.6 18.7 19.0 18.9 18.8 - 
(B6 x 129)F2 SEB 17.0 12.5 13.3 13.5 14.3 - 
13~m -j PBS 18.4 18.9 18.6 18.8 19.t - 
i~2m -/ SEB 20.2 20.0 19.1 18.9 18.4 - 
a Experiments were done as described in Figure 1. B6 mice and 
(B6 x 129)F2 mice served as controls. There were 4 mice per group 
in each experiment. 
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Figure 2. FACS Profiles of Data from Table 3, in FACS Assay, at 
E:T Ratio of 2.5:1 
(A) The profile of control group (without L3). The ratio of specific targets/ 
nonspecific targets was 2.0. 
(B) The profile of experimental group (with L3). The ratio of specific 
targets/nonspecific targets was 0.70. Therefore, the specific CTL activ- 
ity of L3 cells was calculated as (2.0 - 0.7) / 2.0 = 65%. 
Immunity 
188 
Table 3: A Comparison of CTL Activity of L3 Cells in Both FACS 
Assay and ~lCr Release Assay 
Specific cytotoxicity (percentage) 
E:T ratio 
Target Cells 5:1 2.5:1 1.25:1 
FACS Assay a 
P815 + EL4 75 65 43 
~CR Release Assay ~ 
P815 72 57 44 
EL4 1.5 0.6 1.0 
a In the FACS assay, specific targets P815 and nonspecific targets 
EL4 were mixed in a 2:1 ratio, then L3 cells were added to the mixed 
targets at different E:T ratio. Targets without L3 cells served as control. 
After 4 hr of incubation, the cells were stained with F-34.1.2 and APC- 
53-6.72, and the data was analyzed as described in Experimental 
Procedures. 
b In the slCR release assay, P815 and EL4 cells were labeled with 
SlCr: then L3 cells were added to both targets at different E:T ratio 
separately. After 4 hr of incubation, the supernatant was harvested, 
the radioactivity was counted and specific cytolysis was calculated as 
described in Experimental Procedures. 
SEE to generate cell lines with varying numbers  of VI38 + 
and VI38 (containing VI311+) cells. The di f ferences of the 
ratio of VI38 + versus V~8- T cells in cultures with and with- 
out effectors reflects the specif ic deletion of VI~8 + cells. We 
s imultaneously measured the ratio of VI311+/VI31 - cells as 
a specif icity control. As  shown, CD8 + Vl38- T cells deleted 
the CD4 ÷ V~8 + T cells but not CD4 + VI38- T cells. This was 
shown by the decreased ratio of CD4 ÷ VI38÷/CD4 + VI~8- 
(V~8+/V~8 -) and, as expected,  the increased ratio of CD4 + 
VI~I 1÷/CD4 + V611-  (V1311+/V611-) in target cells. One ex- 
planation of the preceding exper iments  was  that specif icity 
was  not only a function of the TCR VI3 used by the target 
T cells, but was  inf luenced by the different superant igens 
used to generate the targets. To exclude this possibility, 
we took advantage of the observat ion that SEB act ivates 
VI37 + and VI317 + as well as Vl38 + T cells in BALB/c  mice 
(Marrack and Kappler, 1990), and used $EB to generate 
both CD4 ÷ VI38 + and CD4 + VI38- targets. Thesetargets  
were  derived either from purif ied total CD4 + T cells st imu- 
lated by SEB (Table 5, exper iments  1 and 2), or from puri- 
fied CD4 + VI~8 + and purified CD4 + V{38- T cells st imulated 
by SEB separately,  and mixed at a VI[38+/VI~8 ratio of 1: 
1 before the test (Table 5, exper iment  3). Again,  only TCR 
VI38-specific cytotoxicity was  observed. These data also 
rule out SEB carryover as a mechanism of TCR VI38- 
specif ic cytotoxicity, because if SEB carryover was in- 
volved in the CD8 ÷ T ce l l -med ia ted  killing, there should 
have been comparab le  killing in both V~8 + and VI38- popu- 
lations. This was  not observed,  even though the VI38- T 
cell population contains SEB-react ive cells including those 
expressing VI37 and V617. Taken together,  these data 
strongly suggest  that the CD8 + T cell line initially induced 
by CD4 ÷ VI38 + cells di f ferentiate into killer cells that specifi- 
cally lyse CD4 ÷ VI38 + targets. 
However,  because the FACS assay quantitatively mea- 
sures the fraction of VI38 + cells present after 24 hr of cul- 
Table 4. TCR V68-Specific CD8+T Cells Selectively Deleted CD4 ÷ VJ38 + T Cells but Not CD4 + Vl38 T Cells in Mixed T Cell Cultures 
Ratio of CD4 + V68+/ Ratio of CD4 + VI~I 1 + 
Targets CD4 ÷ V~8 CD4 + V!811 
CD8 ÷ Plus Percentage 
Experiment Effector E:T CD8 + of specific Plus CD8 + 
number Cells StimulanP Cells Ratio Control effectors deletion Control effectors 
1 CD4 + SEB (1) plus SEE (0.1) CTL-1 4:1 0.47 0.34 27.6 0.14 0.16 (0.16) b 
2 CD4 ÷ SEB (1) plus SEE (0.1) CTL-2 2:1 0.31 0.24 22.5 0.17 0.18 (0.18) 
1:1 0.23 25.8 0.18 (0.18) 
3 CD4 ÷ SEB (1) plus SEE (0.1) CTL-2 2:1 0.32 0.24 25.0 0.18 0.19 (0.19) 
1:1 0.23 28.1 0.19 (0.19) 
4 CD4 ÷ SEB (1) plus SEE (0.025) CTL-2 2:1 3.20 2.00 37.5 0.04 0.05 (0.05) 
1:1 1.94 39.3 0.06 (0.05) 
5 CD4 ÷ SEB (1) plus SEE (0.025) CTL-3 2:1 4.60 3.37 26.7 - - 
1:1 3.54 23.0 - - 
CTL-4 2:1 3.57 25.8 - - 
1:1 3.59 22.0 - - 
Target T cells were purified CD4 ÷ T cells from BALB/c mice stimulated with SEB and SEE, and TCR VI38-specific CD8+VI38 CTL lines were 
prepared as described in Experimental Procedures. Target cells were cultured alone (control) or mixed with the CD8 + CTL lines (plus CD8 ÷ effectors) 
at the indicated ratios and cultured for 24 hr in the presence of IL-2 (10 U/ml). The cells were then divided into two tubes, washed, and stained 
with F-53.6.72 and biotin-F23.1 or biotin-RR-3.15 and analyzed as described in Figure 1. For data anaiysis, the CD8+T cells were gated out and 
the data were expressed as the ratio of CD4 ÷ V~8 ÷ T cells versus CD4 ÷ V~,8- T cells (V~8+NI38 ) or CD4 + V~I 1 ÷ T cells versus CD4 ÷ VI~I 1 - cells 
(VI311 +Nl~l 1 -). 
The percentage of the specific deletion of CD4 + V~8" T cells was calculated as: 
VI~8+N~8 - of control - VI38*NI~8 of experimental 
- x 100% 
V~8÷NI~8 - of control 
a To obtain different ratios of CD4 ÷ V.68*/CD4 + V~8- of target populations in SEB/SEE cultures, same amount of SEB (1 p~m/ml) and different 
amount of SEE (#g/ml) were added in CD4 ÷ T cell cultures as indicated. 
b The values in parentheses are the theoretical calculated values of the CD4 ÷ VI311+/CD4+V611 - ratio if CD4 ÷ VI311 ÷ T cells in the targets were not 
deleted by the CD8 ÷ T cells. 
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Table 5. TCR VI38-Specific CD8 + T Cells Selectively Deleted CD4 + VI~8 ÷ T Cells but Not CD4 + V~8 T Cells in Mixed T Cell Cultures 
Ratio of CD4 ÷ 
V[58+/CD4 +VI~8 
Percentage of 
CD8 + Effector Plus CD8 + specific deletion 
Experiment number Target Cells Cells E:T Ratio Control effectors (CD4 + VI~8 ÷) 
CTL-3 2:1 5.50 28.9 
1 CD4 ÷ 8.2O 
CTL-4 2:1 6.00 26.8 
CTL-3 2:1 6.26 26.3 2 CD4 + 8.49 
CTL-4 2:1 6.23 26.8 
2:1 0.71 32.4 
CTL-3 3 CD4÷V~8 +plus CD4 ~ VI~8 1:1 1.05 0.72 31.4 
2:1 0.73 30.5 CTL-4 
1.1 0.74 29.5 
The experiments were performed as in Table 4. Target ceils were stimulated with SEB only. To obtain different initial VI38+NI~8 ratios, total purified 
CD4 ÷ T cells were stimulated with SEB (1 i~g/ml) (Experiments 1 and 2) or purified CD4 ÷ Vl38 + and CD4 ÷ VI~8 T cells were stimulated with SEB 
(1 #g/ml) separately and mixed in a 1:1 ratio prior to use as targets (Experiment 3). 
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Figure 3. TCR V~8-Specific CD8 ÷ T Ceils Killed CD4 ÷ Vl38 + Target T 
Cells but Not CD4 + VI~8- Target T Cells 
5~Cr-release assay was used to detect the killing capacity of TCR VI38- 
specific CD8 + V#8- T cell lines. SEB-activated CD4 + V~8 + T cells and 
SEE-activated CD4 ÷ VI~8- T cells (prepared as described in Experimen- 
tal Procedures) were used as specific and nonspecific targets. This 
figure represents data from three separate experiments with four inde- 
pendent CTL lines. 
ture, one interpretation of the above data was that the 
VI38 ÷ cells were not killed but merely suppressed in growth. 
To determine directly whether cell lysis was occurring, we 
cocultured CD8 ÷ effectors with the CD4 ÷ VI38 + or CD4 + 
VI~8 targets separately at varying effector:target ratios for 
12 hr and assayed cell lysis by measuring specific slCr 
release. As shown in Figure 3, four independent CD8 ÷ T 
cell lines specifically lysed the CD4 ÷ VI38 ÷ T cell targets. 
The Vp8-Specific In Vitro Cytotoxicity Mediated by 
CD8 ÷ T Cells Is Dependent on p2m-Associated 
Molecules 
Because CD8 ÷ cytotoxic T cells usually recognize antigens 
associated with MHC class I molecules, we asked whether 
CD4 ÷ VI38 + target cells derived from ~2m -/ mice would be 
lysed by the VI38-specific CD8 ÷ CTL. Thus, VI38-specific 
CTLs derived from B6 mice were added to CD4 ÷ VI~8 + and 
CD4 ÷ VI38- targets from B6 mice or from 132m-/-mice, and 
deletion of CD4 ÷ VI~8 + cells was assayed by FACS. No 
deletion of CD4 + VI58 ÷ cells was observed when targets 
were derived from the 132m -/- mice (Table 6). These same 
132m -/- targets were susceptible to killing in a mitogen (con- 
canavalin A [ConA])-induced MHC class I- independent 
assay (data not shown). Furthermore, deletion of CD4 + 
Vl38 ÷ T cells was readily observed in the control B6 targets 
(Table 6). Taken together, these data show that the VI~8- 
specific in vitro cytotoxicity mediated by CD8 ÷ T cells is 
dependent on 152m-associated molecules. 
The Vp8-Specific In Vitro Cytotoxicity Mediated by 
CD8 + T Cells Is Not Blocked by Antibody to MHC 
Class la Molecules 
The next set of experiments were designed to identify 
which 132m-associated molecules were involved in the VI38- 
specific in vitro cytotoxicity mediated by CD8 ÷ T cells. Be- 
cause 132m molecules are known to be associated with 
MHC class I, we first asked whether antibodies known 
to block classical MHC class I-restricted allogeneic CTL 
responses would also inhibit the CD8 + cells mediating VI38- 
specific killing of syngeneic CD4 + cells, For these experi- 
ments, we used the Ml/42.39 antibody, which is a rat anti- 
mouse H-2 monoclonal antibody (MAb) known to be 
specific for all H-2 haplotypes, including H-2K ~ and H-2D ~ 
and H-2L ~ MHC class I antigens (Stallcup et al., 1981). In 
the first set of experiments, we demonstrated the effective- 
ness of the M 1 •42.39 antibody in blocking allospecific cyto- 
toxicity. We used L3 cells, which are H-2 b CD8 ÷ allospecific 
killers and efficiently lyse allogeneic P815 (H-2 d) targets, 
and tested cytotoxicity in the presence or absence of the 
Ml/42.39 antibody or control normal rat immunoglobulin. 
These experiments howed that M 1/42.39 but not the con- 
trol rat immunoglobulin markedly inhibited the lysis of P815 
allogeneic targets over a range of antibody concentration 
from 800-25 ~g/ml (data not shown). We next tested the 
effectiveness of the Ml/42.39 antibody in blocking the 
CD8 ÷ cells mediating Vl~8-specific killing of syngeneic 
CD4 ÷ cells in BALB/c mice (H-2~). V~8-specific CD8 ÷ killers 
were generated as before, and cytotoxicity of CD4 ÷ VI38 + 
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Table 6. CD4 ÷ V~8+T Cells from 1~2m ~ Mice Can Not Be Killed by Syngenic TCR Vl~8-Specific CTLs 
Ratio of CD4 + V~8÷/CD4 + V~,8- 
CD4+ 
Experiment Target E:T CD8 + 
number Cells Ratio Control effectors 
Percentage 
of specific 
deletion 
(CD4* V~8 +) 
2:1 0.26 21.2 C57BL/6 0.33 1 1:1 0.27 18.2 
2:1 0.89 3.3 
~2m-J 1:1 0.92 1.00 -8.6 
2:1 0.32 28.9 C57BL/6 0.45 1:1 0.33 26.7 
2 2:1 0.58 3.3 
~2m+ 1:1 0.60 0.59 1.7 
CD4 + VI~8 + and CD4 + V~8- targets from B6 and 62m J mice were stimulated with SEB, and served as targets. TCR VI38-specific CTLs were prepared 
from B6 mice as described in Experimental Procedures. 
targets tested in the presence or absence of M1/42.39 or 
control rat immunoglobulin. In four separate experiments, 
the Ml/42.39 antibody, although highly efficient in blocking 
conventional CTL directed against H-2 ~ at 25 p,g/ml, does 
not block the V[38-specific killing of CD4 ÷ targets at 200 
i~g/ml, even though the targets express the H-2 ~ MHC 
class I alleles recognized by the Ml/42.39 MAb (data not 
shown). These data suggest that the MHC class la deter- 
minants recognized by Ml/42.39 antibody are not involved 
in the cytotoxicity mediated by the VI38-specific CD8 + killer 
cells. These data are consistent with the analysis of VI3-spe- 
cific CD8 ÷ killer cells in man, which are not inhibited by 
the antibody W6/32 known to be reactive with all known 
MHC class la molecules (Ware et al., 1995 [this issue of 
Immunity]) .  
The Vp8-Specific In Vitro Cytotoxicity Mediated by 
CD8 ÷ T Cells Is Efficiently Blocked by Antiserum 
to the MHC Class Ib Molecule, Qa-1 
The above data demonstrated that although the Vl~8- 
specific in vitro cytotoxicity of CD4 + cells mediated by CD8 ÷ 
T cells is dependent on 132m-associated molecules, anti- 
body to the classical MHC class la molecules did not block 
the cytotoxicity. These data raised the possibility that other 
132m-associated molecules, including MHC class Ib mole- 
cules, might be involved as target structures for the V~- 
specific killers. Moreover, because the M HC class Ib mole- 
cule, Qa-1, has previously been implicated as defining 
populations of regulatory cells important in immune sup- 
pression (Eardley et al., 1978), we reasoned that Qa-1 
might be involved as a structure expressed on CD4 ÷ cells 
in the CD8 ÷ T cell-mediated V~-specific killing we were 
observing. To test this idea, we performed a series of 
blocking studies using well-characterized sera, which ini- 
tially defined the Qa-la and Qa-lb alleles. In initial experi- 
ments, we showed that the Qa-lb but not the Qa-la deter- 
minant was expressed on the CD4 + target cells derived 
from BALB/c mice. We also showed that the antisera to 
Qa-la and Qa-lb did not block the killing of P815 target 
cells by CD8 ÷ anti-MHC class la allogeneic killer L3 cells 
(data not shown). These data indicated that the Qa-la 
and Qa-lb antisera were not nonspecifically capable of 
blocking cell-mediated cytotoxicity. We next tested the ef- 
fectiveness of the anti-Qa-lb antiserum in blocking the 
CD8 + T cell-mediated VI38-specific killing of syngeneic 
CD4 ÷ cells in BALB/c mice and used anti-Qa-la antiserum 
as a specificity control. VI38-specific CD8 ÷ killers were gen- 
erated as before and cytotoxicity of CD4 ÷ VJ38 + targets 
tested in the presence or absence of Qa-la and Qa-lb 
antisera (Table 7). In six separate experiments, we showed 
that Vl~-specific ytotoxicity was blocked by the specific 
Qa-lb antiserum but not by Qa-la antiserum. 
Discussion 
In the present studies, we demonstrated that CD8 + T cells 
participate in the in vivo regulation of CD4 ÷ V138 + T cells 
following SEB administration. We initially confirmed the 
work of others (Kawabe and Ochi, 1991), which has shown 
a deletion of 30%-40% of CD4 ÷ Vl~8 + cells 7-14 days after 
a single injection of SEB in mice. Then, we specifically 
showed that the down-regulation of CD4 ÷ V~8 + T cells be- 
low baseline is not observed in mice depleted of CD8 ÷ 
cells by treatment with anti-CD8 MAb or in CD8 ÷ T cell- 
deficient ~2m -~- mice. Moreover, we observed that follow- 
ing SEB administration, splenic and lymph node CD8 ÷ T 
cells preferentially recognizing CD4 ÷ VI~8 + T cells are gen- 
erated and can be specifically expanded in vitro. These 
CD8 + T cells are cytotoxic to autologous CD4 + VI38 + T cells 
but not to autologous CD4 + VI~8- T cells. Furthermore, we 
demonstrated that this autologous TCR VI3-specific cyto- 
toxicity is dependent on recognition of 132m-associated mole- 
cules and is inhibited by antiserum specific for Qa-1 mole- 
cules but not by antibody to classical MHC class la 
molecules. Together, these data support the idea that the 
specificity of immune regulation may be mediated in part 
by specific recognition by CD8 ÷ T cells of TCR Vi3 chains 
or peptides derived from TCR VI3 chains bound to Qa-1 
MHC class Ib molecules expressed on the surface of autol- 
ogous CD4 + T cells. 
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Table 7. Antimurine Qa-lb but Not Anti-Qa-la Antisera Blocked TCR V136-Specific Killing in BALB/c Mice* 
Ratio of CD4 + Vi~8+/CD4 +VI~8 
Plus CD8 + effectors Percentage of 
Experiment VI3-specific Percentage of 
Number Control Minus Ab Plus ~Qa-1 a Plus (~Qa-1 b deletion blocking 
Percentage of 
(~Qa-1 b 
specific blocking 
0.32 0.25 21.9 -- 
1 0.26 19.0 13.2 
0.33 0 100 86.8 
0.23 0.16 30.4 
2 0.17 26.1 14.1 
0.24 0 100 85.9 
0.88 0.52 40.9 -- 
3 0.55 37.5 8.3 
0.74 15,9 61.1 52.8 
0.38 0.24 36.8 
4 0.25 34,2 7.1 
0.34 10.5 71.5 64.4 
0.58 0.32 44.8 -- 
5 0.34 41.4 7.6 
0.59 0 100 92.4 
0.76 0.54 28.9 -- 
6 0.53 30.3 0 
0.73 3.9 86.5 86.5 
* TCR V138-specific CD8+T cells and CD4 ÷ VI~8 +, CD4 + Vl~8- targets were prepared and experiments were performed as described in Table 5. 
Anti-Qa-1 sera were added at a final dilution of 1:10 to the targets and incubated at room temperature for 30 min before mixed with effector cells. 
Percentage of blocking of killing was calculated as: I[percentage of killing of control group (without antisera) minus percentage of killing of 
experimental group (with antisera)] / percentage of killing of control groupl x 100o/o. 
The evidence that CD8 ÷ T cells arise that are specific 
for CD4 ÷ cells expressing particular VI3 TCRs was demon- 
strated by showing that CD8 ÷ T cells obtained by stimula- 
tion with SEB-activated CD4 ÷ VI38 + T cells only kill SEB- 
activated CD4 ÷ VI38 ÷ T cells but not SEB-activated CD4 ÷ 
Vl38- T cells, even though SEB activates VI37 ÷ and Vl317 + 
T cells as well as VI38 ÷ T cells in BALB/c mice. We assayed 
the destruction of CD4 ÷ cells by a conventional 51Cr release 
assay, as well as by measuring the change in the ratio of 
VI38÷NI~8 - cells induced by CD8 ÷ effector cell in mixed T 
cell culture by FACS. The killing observed is not related 
to T cell activation alone, because VI.~8 + and Vi~8 targets 
cells were both activated. Further, the killing is not depen- 
dent on the particular superantigen used, because V138- 
T cells activated either by SEB or SEE were not killed, 
whereas Vl38 + cells activated by SEB were killed. 
The precise molecular target structure for the Vl~-specific 
CD8 ÷ T cells demonstrated here is unknown. Our studies 
do not formally exclude the possibility that the TCR VI3-spe- 
cific CD8 ÷ T cells described here recognize the whole TCR 
VI~ chain in association with MHC class I molecules. How- 
ever, because CD8 + T cells usually recognize target cells 
expressing particular MHC class I -pept ide complexes, it 
is more likely that these Vl3-specific CD8 ÷ T cells recognize 
MHC class I molecules complexed to peptides derived 
from TCR V13 chains on target T cells. The hypothesis that 
the self-TCR antigens must either be associated with or 
presented by MHC class I molecules is supported by our 
findings that target cells derived from 132m ~- mice, which 
are devoid of both MHC class la and MHC class Ib mole- 
cules, do not function as targets for the Vl3-specific CD8 ÷ 
effector cells. It is of interest to point out that owing to the 
limited polymorphism and tissue-restricted expression of 
MHC class Ib molecules, they may be highly appropriate 
for the presentation of endogenous self-peptides (Stroy- 
nowski, 1990; Joyce et al., 1994; Aldrich et al., 1994). The 
data obtained from our in vitro experiments that the TCR 
Vl~-specific killing mediated by the CD8 + T cells could be 
blocked by anti-Qa-1 antiserum but not anti-MHC class la 
antibody strongly suggested that Qa-1 molecules are the 
major self-TCR peptide-presenting molecules in this par- 
ticular T-T  cell interaction, Since anti-Qa-1 serum only 
blocked about 70° - -80% of the TCR VI3-specific killing in 
our experiments, we could not exclude the possibility that 
other MHC class Ib molecules are also involved in this 
cellular event. On the other hand, our finding that a mono- 
clonal pan anti-class la antibody, Ml /42.39,  did not inhibit 
Vl~-restricted cytotoxicity is against a role for class la MHC 
in our system. The results from the companion paper 
(Ware et al., 1995) that anti-human MHC class la antibody 
W6/32 did not block VI3-specific cytotoxicity mediated by 
human CD8 ÷ T cells further support the hypothesis that 
nonpolymorphic MHC class Ib molecules are the major 
presenting molecules involved. Moreover, studies in EAE 
also suggest that nonpolymorphic MHC class Ib molecules 
can be important in immune regulation. Sun et al. (1988) 
isolated a CD8 ÷ T cell line from EAE rats induced by the 
encephal itogenic CD4 ÷ T cell line $1. This autologous anti- 
S1 CD8 ÷ T cell line proliferated when cultured with $1 
cells, but not when cultured with MBP presented by classi- 
cal APCs. Moreover, the anti-S1 CD8 ÷ T cells were cyto- 
toxic to $1 cells, and the specific proliferation of the CD8 ÷ 
T cells to $1 cells could not be blocked by anti-MHC class 
la antibody. In addition, it is interesting that studies of 
regulatory T suppressors indicated that the CD4 ÷ inducers 
of CD8 ÷ suppressors expressed high levels of the Qa-1 
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molecules and, if the inducer population was depleted of 
Qa-l-expressing T cells, they lost the capacity of inducing 
T suppressors (Eardley et al., 1978). Our data, viewed in 
this light, supports the possibility that Qa-1 molecules may 
play a role in the control of immune responses by pres- 
enting self-TCR peptides to regulatory CD8 ÷ T cells. 
The in vitro experiments how that the CD8 ÷ effector 
cells killed the specific CD4 ÷ targets at low E:T ratios. 
However, the maximum fraction of CD4 ÷ VI38 + cells lysed 
was only approximately 30%. There are several possible 
explanations for such partial killing of target T cells in vitro. 
First, the expression of Qa-1/TCR V6 target structure may 
not be present in sufficient quantity on all targets and limit 
the number of cells killed. Second, Qa-1 + and Qa-1- CD4 + 
T cells with differential susceptibility to killing may emerge 
following antigen activation. Third, it has been shown that 
most of the CD4 ÷ V~8 ÷ T cells that survived 10-14 days 
after SEB administration in vivo were anergic (Rellahan 
et al., 1990; Kawabe and Ochi, 1990). This raises the pos- 
sibility that the state of anergy of CD4 ÷ T cells is correlated 
to their susceptibility to the lysis. In addition, it is known 
that the interactions between cytotoxic T cells and their 
specific targets is not only dependent on cognitive recogni- 
tion between TCR and specific antigen-MHC complexes, 
but is also dependent on the interactions of adhesive mole- 
cules, including CD2, VLA, LFA1, and LFA3 (Williams and 
Barclay, 1988; Staunton et al., 1988; Shimizu et al., 1990). 
The expression of these molecules may also vary with T 
cell activation and limit killing mediated by CD8 ÷ VI3-specific 
effector cells. 
It is of interest o relate the in vitro cytotoxicity observed 
to the SEB-induced delayed CD8 ÷ T cell-dependent dele- 
tion (4-21 days after SEB administration) of CD4 ÷ V~8 ÷ T 
cells observed in vivo. (Figure 1; Table 2). The mecha- 
nisms of this CD8 ÷ T cell-dependent CD4 ÷ T cell deletion 
in vivo is most likely complex. We envision that populations 
of V138-specific CD8 + T cells are initially stimulated by SEB- 
reactive CD4 ÷ VI38 + T cells to grow and differentiate. These 
VI38-specific CD8 ÷ T cells most likely secrete a variety 
lymphokines, which directly or indirectly may be responsi- 
ble for the death of activated VI38-expressing CD4 ÷ T cells. 
In addition, the deletion of CD4 ÷ T cells could result from 
the direct cytotoxic T effector function of the Vl~8-specific 
CD8 ÷ killer cells we have documented in vitro. The relation- 
ship between our in vitro and in vivo data is also highlighted 
by the present experiments using 1~2m ~ mice. In these 
CD8 ÷ T cell-deficient animals, there is no delayed deletion 
of CD4 ÷ V[38 ÷ T cells below baseline (Table 2) and, perhaps 
as important, CD4 + V~8 + targets cells from the 132m + mice 
are not lysed by CD8 ÷ effector cells derived from syngeneic 
~2m ÷ mice (Table 6). 
The idea that regulatory CD8 ÷ T cells that recognize 
TCR target structures expressed on CD4 ÷ T cells are im- 
portant in the control of immune responses in vivo is sup- 
ported by several other lines of investigation. First, in stud- 
ies of EAE in mice, rats, and humans, it has been shown 
that encephalitogenic T cells expressing specific V~ seg- 
ments can induce autoregulatory T cells (Sun et al., 1988; 
Cohen and Weiner, 1988; Lider et ai., 1988; Lohse et al., 
1989; Zhang et al., 1993). Moreover, TCR peptides derived 
from encephalitogenic CD4 + T cells could protect animals 
from the development of EAE in vivo (Offner et al., 1991; 
Vandenbark et al., 1989; Howell et al., 1989). Further, it 
has been shown that CD8 ÷ CTL emerge in rats that have 
recovered from EAE induced by an encephalitogenic CD4 ÷ 
cell line (Sun et al., 1988). These CD8 ÷ CTL are specific 
for the inducing Tcell line and, importantly, efficiently neu- 
tralize the encephalitogenic functions of the inducing cells 
in vivo. In addition, it has recently been shown that in the 
EAE model in mice, regulatory CD4 ÷ T cells also emerge, 
which down-regulate the antigen-specific immune re- 
sponse mediated by CD4 ÷ VI38.2 ÷ T cells (Kumar and Ser- 
carz, 1993). However, even these regulatory CD4 ÷ cells 
were shown to be CD8 + T cell dependent. Thus, immuno- 
regulatory networks involving regulatory CD4 + and CD8 ÷ 
T cells both recognizing TCR V~ segments may ultimately 
control the immune response in EAE. Furthermore, more 
than a decade ago, Kimura and Wilson (1984) showed 
that during the development of graft-versus-host disease 
in rats, CD8 ÷ CTL derived from A/B F1 strain rats emerge 
that specifically kill A strain anti-MHC B CD4 ÷ T blasts 
but do not kill A strain anti-MHC C CD4 + T blasts. These 
cytotoxic CD8 + T cells do kill anti-MHC B CD4 + T blasts 
from a third party, strain C. Thus, like the CD8 ÷ CTL de- 
scribed in this paper, these CTL recognize a common tar- 
get structure expressed on CD4 ÷ T blasts derived from 
MHC A or C strain, which is most likely the TCRs specific 
for MHC B alloantigen. Interestingly, these CTL are not 
restricted by classical polymorphic MHC class la mole- 
cules. This kind of CTL might be responsible for the resis- 
tance of graft-versus-host disease induced by previous 
inoculation of T cells from one of the parental strain in F1 
rats in vivo. 
Because we have only studied SEB-treated mice in this 
study, we do not know whether the delayed and profound 
deletion of other V6 T cell families induced by other super- 
antigens, like the deletion of VI33 T cells induced by SEA 
(McCormack et al., 1993, 1994), are due to a similar mech- 
anism involving CD8 ÷ cells recognizing Qa-1/TCR V~ struc- 
tures on CD4 ÷ T cells. It is possible that VI38 families, which 
are known to be involved in EAE and other autoimmune 
states in mice and rats, are unique. However, we would 
like to believe that our results are not confined to V~8 in 
mice, and experimental support for this notion is present 
in the accompanying paper (Ware et al., 1995). There, we 
demonstrate that human CD8 ÷ T clones specific for TCR 
V6s can be induced in vitro by superantigen-activated au- 
tologous CD4 ÷ T cell clones. These human CD8 + T clones 
specifically recognize and kill autologous clones of CD4 ÷ 
target cells expressing particular V~ TCRs. This killing is 
not inhibited by antibody to human MHC class la mole- 
cules. Thus, the TCR VI3-specific cytotoxicity mediated by 
CD8 ÷ T cells reported here appears to represent a more 
general phenomenon, and may play important physiolog- 
ical roles in immunoregulation and in control of autoim- 
munity. 
Experimental Procedures 
Animals 
BALB/c mice, C57BL/6J (B6) mice, ~m ~ mice, and 129B6F2/J control 
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mice (female, 6-12 weeks old) were purchased from Jackson Labora- 
tories (Bar Harbor, Maine), and maintained in our animal facilities. 
Antibodies and Antisera 
Fluerescein (FI) or allophycocyanin (APC) 53-6.72 (anti-mouse CDS), 
FI-34.1.2 (anti mouse H-2d), APC-GK1.5 (anti-mouse CD4), biotin- 
F23.1 (anti-mouse TCR V~8.1-3), biotin-K J-16 (anti-mouse TCR 
V~8.1,2), and biotin-RR3.15 (anti-mouse V~I 1) were purified from the 
ascites of correspondent hybridomas and conjugated in our laboratory. 
Biotin-RR4.7 (anti-mouse TCR VI~6) was purchased from Pharmingen 
(San Diego, California). M'i/42.39 was purified from the supematant 
of the hybridoma culture using a protein G column. Anti-Qa-la and 
anti-Qa-lb antisera were prepared as described previously (Boyse et 
al., 1972; Stanton and Boyse, 1979; Eardley st al., 1978). 
Cell Lines 
L3 cells, an allo-reactive CD8 ÷ CTL line from C57BL/6J strain specific 
to H-2 d alloantigen, were provided by Dr. G. Siu of Columbia University 
(Glasebrook and Fitch, 1979). These cells were cultured in Clicks' 
HEAA medium (Irvine Scientific, Santa Aria, California), supplemented 
with 10% fetal calf serum, 100 U/ml of penicillin and streptomycin, 
2 rnM ~-mercaptoethanol, and 25 U/ml of human interleukin-2 (IL-2) 
(DandR Systems, Incorporated, Minneapolis, Minnesota). The L3 line 
was maintained by stimulation with irradiated (3,000 rads) spleen cells 
from BALB/c mice at a 1:5 to 1:10 ratio, every 10-14 days. The P815 
(H-2 ~) and EL4 (H-2 b) murine cell lines were obtained from the American 
Type Culture Collection, maintained in RPMI 1640 medium supple- 
mented with 10% fetal calf serum, 100 U/ml of penicillin and streptomy- 
cin, and 2 mM 13-mercaptoethanol. 
Generation of TCR VJ~8-Specific CTL Lines 
Pooled spleen and lymph node cells from four SEB-primed mice (4-14 
days after SEB injection) were first depleted of B cells, by incubating 
with goat anti-mouse immunoglobulin and goat anti-rat immunoglobu- 
lin coated magnetic beads (Advanced Magnetic, Incorporated, Cam- 
bridge, Massachusetts) at a ratio of 1 x 107 cells per ml of beads for 
30 rain at 4°C. The cells were separated from beads by a Bio Mag 
Separator (Advanced Magnetic, Incorporated, Cambridge, Massachu- 
setts), and the unbound cells were then depleted of V~8 ÷ T cells by 
using the anti-mouse TCR V~8 MAb, F23.1 (1 x 107, 10 I~g). The cells 
from the second round of negative selection were positively selected 
for CD8 + cells by incubating 1 x 10 ~ cells with 0.1 ml of 1:40 ascites 
of 53-6.72 (anti-mouse CDB), followed by incubation with goat anti-rat 
coated beads and subsequent magnetic separation. The cells bound 
to the beads were incubated overnight at 37°C to allow their dissocia- 
tion from beads. The final purified population consisted of CD8* V B8- 
T cells (>95%). The CD8 ÷ V[38 T cells were then incubated with irradi- 
ated (3,000 rads) SEB-activated syngeneic CD4 + V~8 + T cell line (5-10 
days after SEB stimulation) and APCs (syngeneic spleen cells) in a 
1:1:1 ratio, at 37°C, 6% CO2 for 14 days. IL-2 (10 U/ml) (DandR Sys- 
tems, Incorporated, Minneapolis, Minnesota) was added on day 3 of 
the culture. 
Generation of SEB and SEE-Induced CD4 ÷ Target T Cell Lines 
Spleen and lymph node cells from naive mice were first depleted of 
CD8 + T cells and then positively selected for TCR VI~8 + T cells, or 
negatively selected for TCR V~8- T cells. CD4 + V~8 ÷ T cells were 
stimulated with SEB (1 ~g/ml) (Toxin Technology, Madison, Wiscon- 
sin); CD4 + V[56- T cells were stimulated with SEE (0.1 ~g/ml) (Toxin 
Technology); and CD4 + T cells were stimulated with both SER (1 I~g/ 
ml) and SEE (0.025 or 0.1 p.g/ml) or SEB (1 ~g/ml) alone. In all SEB- 
or SEE-primed T cell cultures, irradiated (3000 fads) spleen ceils were 
added as APCs. After 3 days, T cell blasts were isolated and cultured 
in complete IMDM medium supplemented with IL-2 (10 U/ml). The 
phenotypes of these T cells were determined by staining the cells with 
APC-GK1.5, FI-53-6.72, and biotin-F23,1 or biotin-RR-3.15 (anti- 
V~I 1) and analyzed by FACS. 
FACe Analysis for Detecting SEB-Induced TCR V~-Specific 
T Cell Death in Peripheral Blood 
Mice were injected in the tail vein on day 1 with either 50 ~g SEB in 
0.1 ml phosphate-buffered saline (PBS) or PBS alone. One group of 
mice were CD8 + T cell depleted 7 days before SEB/PBS injections as 
previously described (Jiang et al., 1992). On days 4, 7, 14, and 21 
after priming, the mice were examined for numbers of CD4 + VI~8.1,2+; 
CD8 + VI38.1,2 +, CD4 ÷ V~6 +, and CD8 ÷ VI36 ÷ T cells. At each timepoint, 
peripheral blood drawn from the tail vein of 4-6 mice in each group was 
pooled, mononuclear cells were purified on a lymphocyte separation 
medium gradient (Organon Technicka, Durham, North Carolina), and 
stained with the following MAbs: FI-53-6.72 (anti-CD8); APC-GK1.5 
(anti-CD4); and biotin-KJ-16 (anti-Vl~8.1,2) or biotin-RR4.7 (anti-V~6). 
Biotin conjugates were revealed with Texas red-avidin. Dead cells 
were excluded using propidium iodide. Flow cytometric analysis was 
performed on a dual laser FACStar plus (Becton-Dickinson, San Jose, 
California) using FACS/DESK data analysis software (Stanford Univer- 
sity, Stanford, California). The data are expressed as the percent of 
total CD4 ÷ or total CD8 ÷ T cells. 
FACS Analysis for Measuring Specific CTL Activity 
To assay the L3 cell line for H-2 d allospecific killing, we used the H-2 ~- 
expressing target, P815, a CD8- mastocytoma cell line derived from 
DBN2 mice as the positive target. El-4, a H-2b-expreseing CD8- T 
lymphoma line sewed as the negative target. Graded numbers of L3 
effector cells were added to a fixed ratio of H-2 d÷ (specific targets) to 
H-2 ~ (nonspecific targets) for 4 hr prior to FACS analysis (see below). 
The reduction in the ratio of H-2d+/H-2 d- cells in the presence of effecter 
cells, compared with the ratio of target cells in the absence of effectors, 
served as a measure of cell death. 
In the TCR V[58-specific ytolytic system, SEB-activated CD4 • V!58 + 
T cells were used as specific VI38 + targets. In addition, SER plus SEE 
or SEB alone were used to activate CD4 ÷ V~,8 T cells. These CD4 + 
V1~8 served as nonspecific V~8- targets. In this system, the target T 
cells used were from day 4-6 superantigen-activated (SEB or SEE) 
cultures, because we had noted that susceptibility to lysis varied as a 
function of time following superantigen activation and peaked between 
days 4 and 6. Graded numbers of putative CD8 + CTL effector popula- 
tions were then added to V~8 ÷ and V~,8 targets for 24 hr and the ratio 
of VI~8+N~8 cells was measured by FACS. The baseline control was 
the ratio of VI38+N~8 - after 24 hr in the absence of effector cells. 
In both CTL systems, triplicate or duplicate samples were set up 
for each E:T ratio. Following effector to target cell incubation, two-color 
fluorescence was used to distinguish targets from effectors, as well 
as specific from nonspecific targets. Targets and effectors were distin- 
guished by expression of CD8 using the conjugated anti-CD8 antibod- 
ies FI-53-6.72, or APC-53-6.72 antibodies. In the L3 system, cells 
were stained with FI-34.1.2 (anti H-2 d) to distinguish P815 (H-2 ~) from 
EL4 (H-2b). In TCR V[3-specific ytolytic system, cells were stained with 
biotin-F23.1 to distinguish Vl~8 + targets from V[58- targets, or biotin- 
RR3.15 to distinguish V[511 + targets from VI~11- targets. Biotin- 
conjugated reagents were revealed with Texas red-avidin. Dead cells 
were excluded using propidium iodide. For data analysis, the CD8 + T 
cells were gated out and the data was expressed as the ratio of the 
positive stained cells (specific targets) versus negative stained cells 
(nonspecific targets). The percentage of the specific cytolysis of spe- 
cific targets was calculated as 
[([positive stained cells / negative stained cells of control group] - 
[positive stained cells / negative stained cells of experimental group]) / 
[positive stained cells / negative stained cells of control group]/ x 
100% 
51Cr Release Assay 
P815, EL4, SEB-activated CD4 ÷ Vl~8 + T cells, and SEE-activated CD4 + 
VI~8 T cells were labeled with 200 #Ci SlCr (New England Nuclear, 
Boston, Massachusetts) for 45-60 min, washed three times and used 
as targets. L3 effector cells and TCR V~8-specific CD8 ÷ CTL cells 
were added to corresponding targets at varying E:T ratio and incubated 
at 37°C for either 4 hr (standard assay) or 12 hr (special assay). In 
lectin-induced MHC class I-independent cytolysis, ConA was added 
at the beginning of the culture (20-40 p.g/well). After incubation, the 
supernatants were harvested, and radioactivity was counted on a ~' 
counter (LKB, Piscataway, New Jersey). The mean of triplicate sam- 
ples was calculated and the percent specific ~Cr release was deter- 
mined as follows: 
Immunity 
194 
Percentage of specific cytolysis = [(experimental 5tCr release - con- 
trol ~lCr release) / (maximum 5~Cr elease - control ~lCr release)] x 
100% 
Experimental ~'Cr release represents counts from target cells mixed 
with effector cells, control 5~Cr elease represents counts from targets 
incubated with medium alone (spontaneous release), and maximum 
SlCr release represents counts from targets exposed to 5% Triton 
X-100. 
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